Company Overview

Update
Headquarters:
Florham Park, NJ
Funding:
$5.80M
Categories:
Biotechnology

Protalex, Inc., a development stage company, develops a class of biopharmaceutical drugs designed to treat autoimmune and inflammatory

Description

Update

Protalex, Inc., a development stage company, develops a class of biopharmaceutical drugs designed to treat autoimmune and inflammatory diseases, including rheumatoid arthritis. PRTX-100 The company’s lead product, PRTX-100, is a formulation of a proprietary, highly-purified form of the Staphylococcal bacterial protein known as Protein A, which is an immune modulating protein produced by bacteria. PRTX-100 has the ability, at very low concentrations, to bind to and to regulate activation of human B-lymphocytes and macrophages which mediate inflammation in certain autoimmune diseases. PRTX-100 is in Phase 1b clinical trial for the treatment of patients with rheumatoid arthritis. Patents, Trademarks, and Proprietary Technology The company filed an initial therapeutic use patent application with the U.S. Patent and Trademark Office, which issued in May 2007, as U.S. 7,211,258 (the 258 Patent). The 258 Patent has claims relating to the... See More

Current Team (1)

Update

Funding Rounds (2) - $5.80M

Update

Offices/Locations (1)

Update
  • Office

    131 COLUMBIA TURNPIKE AVE

    SUITE 1

    Florham Park, NJ 07932

    USA

Images (1)

Update
  • A9a29c3e527876ac4f517959767f1d66